European surveillance data show on-going transmission of viral hepatitis across the European Union and European Economic Area (EU/EEA). The available notification data however, do not provide a clear epidemiological picture of hepatitis C in Europe. Prevalence data from population surveys are a key source of information to complement the surveillance data for hepatitis C due to the limitations of surveillance for hepatitis: the infection is often asymptomatic and notifications are strongly influenced by local testing practices. The overarching aim of this toolkit is to gain a better understanding of the HCV epidemiology in the EU/EEA.
This technical report presents the epidemiology of human and animal leishmaniases (HumL and AniL) in the European Union (EU) and its neighbouring countries and describes the surveillance, prevention and control measures implemented.
In 2021, ECDC will continue to address the COVID-19 pandemic and support the efforts of Member States and the Commission. The Centre will also start the implementation of a strategy that will guide its efforts towards 2027.
Minutes of the fiftieth meeting on 25 November 2020 (via audio conference) adopted by the ECDC Management Board at its fiftieth meeting on 24 March 2021.
In 2019, the average total (community and hospital sector combined) consumption of antibacterials for systemic use (Anatomical Therapeutic Chemical (ATC) group J01) in the EU/EEA was 19.4 defined daily doses (DDD) per 1 000 inhabitants per day (country range: 9.5–34.1). During the period 2010–2019, a statistically significant decrease was observed for the EU/EEA overall.